Securities Suit Targets Insulet Over Omnipod Manufacturing Disclosures

Overview

• Insulet disclosed a voluntary Medical Device Correction for specific Omnipod 5 lots on March 12, 2026 and another correction covering Omnipod 5, Omnipod Dash and Omnipod Eros lots on May 26, 2026, each disclosure followed by sharp stock declines.
• The filed complaint alleges the company failed to maintain adequate manufacturing controls, creating a foreseeable risk of safety violations and a manufacturing defect that could cause insulin under-delivery.
• Plaintiff-side firms including Faruqi & Faruqi, DJS Law Group, Schall Brown & Schwartz, and the Law Offices of Howard G. Smith are soliciting investors to join the case and to seek lead-plaintiff appointment before the August 31, 2026 deadline.
• The suit cites violations of §§10(b) and 20(a) of the Securities Exchange Act and SEC Rule 10b-5, but the case remains at an early stage with no class certification yet and investors advised to preserve trading records and communications.
• If the case proceeds to discovery and certification it could lead to a settlement or trial and may affect both investor recoveries and scrutiny of device manufacturing oversight given the clinical risks alleged.